The dual-receptor mechanism of tirzepatide can break through weight loss plateaus because it engages a different biological pathway
Eli Lilly and Company, the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), has announced positive topline results from a phase 3 clinical trial evaluating the efficacy and safety of retatrutide, an investigational, first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist, in adults with obesity or overweight and at least one weight-related comorbidity and without diabetes
Common adverse effects associated with probiotic use are typically mild and gastrointestinal in nature: Bloating and gas, especially during the first few days of use Abdominal discomfort or cramping Changes in bowel habits (diarrhea or constipation) Nausea (less common) These symptoms usually resolve within one to two weeks as the gut microbiome adjusts
Retatrutide targets three receptors, offering broader metabolic effects compared to Tirzepatides two
based on their mechanisms, a clinically significant interaction affecting absorption, distribution, metabolism, or excretion of either agent seems unlikely
Appetite regulation often becomes more predictable, and early nausea may decrease or resolve
